Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junsheng Ma

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
Cancer|August 10, 2019
Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanomaGustavo Schvartsman, Junsheng Ma, Roland L Bassett, et al.
BMC Cancer|February 2, 2020
Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutationsRoberto Ruiz-Cordero, Junsheng Ma, Abha Khanna, et al.
The Journal of Investigative Dermatology|February 26, 2019
Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Responses in KIT-Mutant Metastatic MelanomaMeredith McKean, Junna Oba, Junsheng Ma, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 5, 2018
Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin LymphomaYago Nieto, Peter F Thall, Junsheng Ma, et al.
American Journal of Hematology|September 24, 2021
Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: A propensity-score matched analysisRomil Patel, Junsheng Ma, Qaiser Bashir, et al.
Bone Marrow Transplantation|May 24, 2022
A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantationBorje S Andersson, Peter F Thall, Junsheng Ma, et al.
Transplantation and Cellular Therapy|March 25, 2022
Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell TransplantationAimaz Afrough, Oren Pasvolsky, Junsheng Ma, et al.
Leukemia & Lymphoma|April 20, 2022
A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemiaNicholas J Short, Gautam Borthakur, Naveen Pemmaraju, et al.
Journal for Immunotherapy of Cancer|October 12, 2018
Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitisDaniel H Johnson, Chrystia M Zobniw, Van A Trinh, et al.
Transplantation and Cellular Therapy|May 9, 2021
Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell LymphomaJacinth Joseph, Junsheng Ma, Fady Hennawy, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
Cancer|August 10, 2019
Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanomaGustavo Schvartsman, Junsheng Ma, Roland L Bassett, et al.
BMC Cancer|February 2, 2020
Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutationsRoberto Ruiz-Cordero, Junsheng Ma, Abha Khanna, et al.
The Journal of Investigative Dermatology|February 26, 2019
Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Responses in KIT-Mutant Metastatic MelanomaMeredith McKean, Junna Oba, Junsheng Ma, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 5, 2018
Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin LymphomaYago Nieto, Peter F Thall, Junsheng Ma, et al.
American Journal of Hematology|September 24, 2021
Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: A propensity-score matched analysisRomil Patel, Junsheng Ma, Qaiser Bashir, et al.
Bone Marrow Transplantation|May 24, 2022
A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantationBorje S Andersson, Peter F Thall, Junsheng Ma, et al.
Transplantation and Cellular Therapy|March 25, 2022
Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell TransplantationAimaz Afrough, Oren Pasvolsky, Junsheng Ma, et al.
Leukemia & Lymphoma|April 20, 2022
A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemiaNicholas J Short, Gautam Borthakur, Naveen Pemmaraju, et al.
Journal for Immunotherapy of Cancer|October 12, 2018
Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitisDaniel H Johnson, Chrystia M Zobniw, Van A Trinh, et al.
Transplantation and Cellular Therapy|May 9, 2021
Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell LymphomaJacinth Joseph, Junsheng Ma, Fady Hennawy, et al.
Pageof 6